Bringing immunoglobulin knowledge up to date: how should we treat today?
Version of Record online: 15 JUL 2011
© 2011 The Authors. Clinical and Experimental Immunology © 2011 British Society for Immunology
Clinical & Experimental Immunology
Volume 166, Issue 1, pages 16–25, October 2011
How to Cite
Misbah, S., Kuijpers, T., van der Heijden, J., Grimbacher, B., Guzman, D. and Orange, J. (2011), Bringing immunoglobulin knowledge up to date: how should we treat today?. Clinical & Experimental Immunology, 166: 16–25. doi: 10.1111/j.1365-2249.2011.04443.x
- Issue online: 12 SEP 2011
- Version of Record online: 15 JUL 2011
- Accepted for publication 2 June 2011
- IgG receptor;
- intravenous IgG;
- primary immunodeficiencies;
- subcutaneous IgG
Immunoglobulin (Ig) therapy is constantly evolving. Advances in the basic and clinical science of immunoglobulins have provided new perspectives in using polyclonal IgG to treat patients with primary immunodeficiencies. Recent meta-analyses of patient data and outcomes, optimization of IgG administration and better understanding of the IgG receptor variability and clinical effect are new concepts which practising immunologists can use in tailoring their approach to treating patients with primary immunodeficiencies. This manuscript presents the proceedings of a satellite symposium, held in conjunction with the European Society for Immunodeficiencies (ESID) 2010 meeting, to inform attendees about new scientific concepts in IgG therapy, with the goal of empowering expert level evaluation of what optimal IgG therapy is today.